Mice deficient in sphingosine kinase 1 are rendered lymphopenic by FTY720

被引:384
|
作者
Allende, ML
Sasaki, T
Kawai, H
Olivera, A
Mi, YD
van Echten-Deckert, G
Hajdu, R
Rosenbach, M
Keohane, CA
Mandala, S
Spiegel, S
Proia, RL
机构
[1] NIDDK, Genet Dev & Dis Branch, NIH, Bethesda, MD 20892 USA
[2] NIAMSD, NIH, Bethesda, MD 20892 USA
[3] Univ Bonn, Kekule Inst Organ Chem & Biochem, D-53121 Bonn, Germany
[4] Virginia Commonwealth Univ, Dept Biochem, Sch Med, Richmond, VA 23298 USA
[5] Merck & Co Inc, Res Labs, Dept Immunol & Rheumatol, Rahway, NJ 07065 USA
关键词
D O I
10.1074/jbc.M406512200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Sphingosine-1-phosphate (S1P), a lipid signaling molecule that regulates many cellular functions, is synthesized from sphingosine and ATP by the action of sphingosine kinase. Two such kinases have been identified, SPHK1 and SPHK2. To begin to investigate the physiological functions of sphingosine kinase and S1P signaling, we generated mice deficient in SPHK1. Sphk1 null mice were viable, fertile, and without any obvious abnormalities. Total SPHK activity in most Sphk1-/- tissues was substantially, but not completely, reduced indicating the presence of multiple sphingosine kinases. S1P levels in most tissues from the Sphk1 -/- mice were not markedly decreased. In serum, however, there was a significant decrease in the S1P level. Although S1P signaling regulates lymphocyte trafficking, lymphocyte distribution was unaffected in lymphoid organs of Sphk1 -/- mice. The immunosuppressant FTY720 was phosphorylated and elicited lymphopenia in the Sphk1 null mice showing that SPHK1 is not required for the functional activation of this sphingosine analogue prodrug. The results with these Sphk1 null mice reveal that some key physiologic processes that require S1P receptor signaling, such as vascular development and proper lymphocyte distribution, can occur in the absence of SPHK1.
引用
收藏
页码:52487 / 52492
页数:6
相关论文
共 50 条
  • [1] The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2
    Paugh, SW
    Payne, SG
    Barbour, SE
    Milstien, S
    Spiegel, S
    FEBS LETTERS, 2003, 554 (1-2) : 189 - 193
  • [2] The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in Apolipoprotein E-deficient mice
    Keul, P.
    Toelle, M.
    Lucke, S.
    Lipinski, K. Von Wnuck
    Heusch, G.
    Schuchardt, M.
    Van der Giet, M.
    Levkau, B.
    EUROPEAN HEART JOURNAL, 2007, 28 : 796 - 797
  • [3] The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein E-deficient mice
    Keul, Petra
    Toelle, Markus
    Lucke, Susann
    Lipinski, Karin von Wnuck
    Heusch, Gerd
    Schuchardt, Mirjam
    van der Giet, Markus
    Levkau, Bodo
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (03) : 607 - 613
  • [4] The sphingosine-1-phosphate analogue FTY720 reduces atherosclerosis in apolipoprotein e-deficient mice
    Keul, Petra
    Toelle, Markus
    Lucke, Susann
    von Wnuck Lipinski, Karin
    Heusch, Gerd
    Schuchardt, Mirjam
    van der Giet, Markus
    Levkau, Bodo
    JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2007, 42 : S224 - S224
  • [5] Sphingosine kinase 2 is required for modulation of lymphocyte traffic by FTY720
    Kharel, Y
    Lee, S
    Snyder, AH
    Sheasley-O'Neill, SL
    Morris, MA
    Setiady, Y
    Zhu, R
    Zigler, MA
    Burcin, TL
    Ley, K
    Tung, KSK
    Engelhard, VH
    Macdonald, TL
    Pearson-White, S
    Lynch, KR
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2005, 280 (44) : 36865 - 36872
  • [6] Sphingosine-1-phosphate analogue FTY720 causes lymphocyte redistribution and hypercholesterolemia in ApoE-deficient mice
    Klingenberg, Roland
    Nofer, Jerzy-Roch
    Rudling, Mats
    Bea, Florian
    Blessing, Erwin
    Preusch, Michael
    Grone, Hermann J.
    Katus, Hugo A.
    Hansson, Goeran K.
    Dengler, Thomas J.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (11) : 2392 - 2399
  • [7] Sphingosine kinase 2 deficient mice exhibit reduced experimental autoimmune encephalomyelitis: Resistance to FTY720 but not ST-968 treatments
    Imeri, Faik
    Schwalm, Stephanie
    Lyck, Ruth
    Zivkovic, Aleksandra
    Stark, Holger
    Engelhardt, Britta
    Pfeilschifter, Josef
    Huwiler, Andrea
    NEUROPHARMACOLOGY, 2016, 105 : 341 - 350
  • [8] Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues
    Hoegnauer, Klemens
    Billich, Andreas
    Pally, Charles
    Streiff, Markus
    Wagner, Trixie
    Welzenbach, Karl
    Nussbaumer, Peter
    CHEMMEDCHEM, 2008, 3 (07) : 1027 - 1029
  • [9] Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases
    Billich, A
    Bornancin, F
    Dévay, P
    Mechtcheriakova, D
    Urtz, N
    Baumruker, T
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (48) : 47408 - 47415
  • [10] Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720
    Zemann, B
    Kinzel, B
    Müller, M
    Reuschel, R
    Mechtcheriakova, D
    Urtz, N
    Bornancin, F
    Baumruker, T
    Billich, A
    BLOOD, 2006, 107 (04) : 1454 - 1458